Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veru Inc. - Common Stock (NQ: VERU )

0.7818 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veru Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized Patients
Veru Inc (NASDAQ: VERU) has  
Via Benzinga
Why Veru Stock Is Surging Today
Veru Inc (NASDAQ: VERU) shares are trading significantly higher Monday after the company reported its novel COVID-19 drug candidate reduced deaths by 55% in hospitalized... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Rise and shine, investor! It's time to start off another week of trading with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Data Committee Recommends Veru's COVID-19 Trial To Continue Unmodified
The Independent Data Monitoring Committee (IDMC) has conducted a planned conditional power analysis of the first 75 randomized patients in Veru Inc's (NASDAQ: VERU)... 
Via Benzinga
Veru Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Veru (NASDAQ:VERU) reported Q1 sales of $14.13 million. Earnings fell to a loss of $6.38 million, resulting in a 48.56% decrease from last quarter. 
Via Benzinga
Veru Q1 Earnings Top Estimates
Via Benzinga
Recap: Veru Q1 Earnings
  Veru (NASDAQ:VERU) reported its Q1 earnings results on Wednesday, February 9, 2022 at 06:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 9, 2022
Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report quarterly earnings at $0.63 per share on revenue of $25.05 billion. 
Via Benzinga
Veru Posts Mixed Q4 Results
Veru Inc (NASDAQ: VERU) reported fourth-quarter FY21 sales growth of 32.8% year-on-year, to $15.65 million, missing the analyst consensus of $18.17 million. FC2... 
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet
Joe Biden is redoubling his efforts to fight cancer with a new "cancer cabinet." Here are the biotech stocks to buy that can benefit. 
Via InvestorPlace
Veru's Cancer Candidate Sabizabulin Gets FDA Fast Track Tag For COVID-19
The FDA has granted Fast Track designation to Veru Inc's (NASDAQ: 
Via Benzinga
48 Biggest Movers From Yesterday
Gainers Splash Beverage Group, Inc. (NYSE: SBEV) shares jumped 70.6% to close at $1.80 on Tuesday after the company announced it received authorization to sell its TapouT... 
Via Benzinga
Veru: Q4 Earnings Insights
Veru (NASDAQ:VERU) reported its Q4 earnings results on Thursday, December 2, 2021 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Veru... 
Via Benzinga
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
Gainers Veru (NASDAQ:VERU) shares moved upwards by 21.5% to $6.49 during Tuesday's regular session. As of 12:31 EST, this security is trading at a volume of 7.0... 
Via Benzinga
30 Stocks Moving In Tuesday's Mid-Day Session
Gainers TSR, Inc. (NASDAQ: TSRI) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year.... 
Via Benzinga
Why Jim Cramer Likes Grab Holdings
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: 
Via Benzinga
How Good Are Veru's Earnings? | Return On Capital Employed
According to Benzinga Pro data, during Q4, Veru (NASDAQ:VERU) posted sales of $15.65 million. Earnings were up 34.84%, but Veru still reported an overall loss of $1.87 million. In... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus U.K. Signs Deal to Buy Incremental COVID-19 Vaccines From Moderna And Pfizer-... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For December 2, 2021
Companies Reporting Before The Bell • EHang Holdings (NASDAQ:EH) is expected to report earnings for its third quarter. • LightInTheBox Holding (NYSE:LITB) is... 
Via Benzinga
Earnings Outlook For Veru
Veru (NASDAQ:VERU) is set to give its latest quarterly earnings report on Thursday, 2021-12-02. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
10 Consumer Staples Stocks Moving In Monday's After-Market Session
Gainers 111 (NASDAQ:YI) shares rose 3.81% to $4.35 during Monday's after-market session. The market value of their outstanding shares is at $360.4 million. The company's, Q3... 
Via Benzinga
Cramer Gives His Take On Change Healthcare, Veru And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Change Healthcare Inc. (NASDAQ: CHNG) is a good, steady firm. Cramer said with Veru Inc. (NASDAQ: VERU)... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Why Veru Stock Vaulted Higher Today
An analyst raised his price target for the stock. 
Via The Motley Fool
Why Veru Stock Blasted Higher on Friday
An analyst argues that the company has far more value than many realize. 
Via The Motley Fool
Veru Stock Gains After Q3 Result Tops Estimates
Veru Inc (NASDAQ: VERU) reported third-quarter FY21 sales growth of 71% year-on-year, to $17.66 million, beating the analyst consensus of $14.10 million. FC2... 
Via Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.